<p>KALA BIO（纳斯达克：KALA - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益（EPS）为 0.86 美元，Zacks 报道。</p>
<h2>KALA BIO 股价下跌 12.0%</h2>
<ul>
<li>Kala Pharmaceuticals 在过去一个月上涨 400%，接下来会怎样？</li>
</ul>
<p>KALA BIO 股票在周三下跌了 0.03 美元，报 0.20 美元。该股票的交易量为 3,346,512 股，而其平均交易量为 6,513,633 股。KALA BIO 的一年最低价为 0.15 美元，一年最高价为 20.60 美元。该公司的市值为 1.8117 亿美元，市盈率为-0.03，贝塔值为-1.98。该公司的 50 日移动平均线为 0.30 美元，200 日移动平均线为 0.65 美元。</p>
<h2>机构投资者对 KALA BIO 的看法</h2>
<p>一些机构投资者和对冲基金最近调整了对 KALA 的持股。Woodline Partners LP 在第一季度购买了 KALA BIO 的新股份，价值约为 1,483,000 美元。Jane Street Group LLC 在第四季度购买了 KALA BIO 的新股份，价值约为 80,000 美元。Virtu Financial LLC 在第四季度购买了 KALA BIO 的新股份，价值约为 48,000 美元。XTX Topco Ltd 在第二季度购买了 KALA BIO 的新股份，价值约为 62,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 KALA BIO 的股份增加了 2.8%。Geode Capital Management LLC 现在拥有该公司 56,367 股股票，价值 268,000 美元，此前在上个季度又购买了 1,534 股。24.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>另外，Weiss Ratings 在 3 月 27 日的报告中重申了对 KALA BIO 股票的 “卖出（e+）” 评级。一位分析师对该股票给予了买入评级，四位分析师给予了持有评级，一位分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，KALA BIO 的平均评级为 “持有”，共识目标价为 20.38 美元。</p>
<p><strong>查看我们关于 KALA 的最新报告</strong></p>
<h2>KALA BIO 公司简介</h2>
<p>（获取免费报告）</p>
<p>KALA Bio 纳斯达克：KALA 是一家商业阶段的生物制药公司，专注于开发和商业化用于眼部疾病的新疗法。该公司的专有表面电荷基础纳米颗粒递送平台旨在增强治疗药物在眼表面的渗透和滞留。这项技术是其主要产品 Eysuvis（KPI-121 1.0%）的基础，该产品是 FDA 批准的用于短期缓解与过敏性结膜炎相关的眼部瘙痒的局部类固醇。</p>
<p>除了其已批准的疗法外，KALA Bio 还在推进一系列针对炎症和退行性眼病的研究药物候选者。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 KALA BIO</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 KALA BIO 吗？</h2>
<p>在你考虑 KALA BIO 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 KALA BIO 并不在名单上。</p>
<p>虽然 KALA BIO 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Kala制药

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

<p>KALA BIO (NASDAQ:KALA) 报告了每股 0.86 美元的季度收益。股价下跌 12% 至 0.20 美元，交易量为 330 万股。机构投资者最近增加了持股比例，对冲基金持有 24.61% 的股份。分析师的评级各不相同，包含一项买入、四项持有和一项卖出，平均目标价为 20.38 美元。KALA BIO 专注于开发眼科疾病的治疗方法，包括其获得 FDA 批准的产品 Eysuvis</p>

<p>KALA BIO (NASDAQ:KALA - Get Free Report) posted its earnings results on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter, Zacks reports.</p>
<div class="lb-trans"><p>KALA BIO（纳斯达克：KALA - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益（EPS）为 0.86 美元，Zacks 报道。</p>
</div><h2>KALA BIO Trading Down 12.0%</h2>
<div class="lb-trans"><h2>KALA BIO 股价下跌 12.0%</h2>
</div><ul>
<li>Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?</li>
</ul>
<div class="lb-trans"><ul>
<li>Kala Pharmaceuticals 在过去一个月上涨 400%，接下来会怎样？</li>
</ul>
</div><p>Shares of KALA BIO stock traded down $0.03 on Wednesday, reaching $0.20. The stock had a trading volume of 3,346,512 shares, compared to its average volume of 6,513,633. KALA BIO has a 1 year low of $0.15 and a 1 year high of $20.60. The company has a market cap of $181.17 million, a P/E ratio of -0.03 and a beta of -1.98. The business's 50 day moving average is $0.30 and its two-hundred day moving average is $0.65.</p>
<div class="lb-trans"><p>KALA BIO 股票在周三下跌了 0.03 美元，报 0.20 美元。该股票的交易量为 3,346,512 股，而其平均交易量为 6,513,633 股。KALA BIO 的一年最低价为 0.15 美元，一年最高价为 20.60 美元。该公司的市值为 1.8117 亿美元，市盈率为-0.03，贝塔值为-1.98。该公司的 50 日移动平均线为 0.30 美元，200 日移动平均线为 0.65 美元。</p>
</div><h2>Institutional Investors Weigh In On KALA BIO</h2>
<div class="lb-trans"><h2>机构投资者对 KALA BIO 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of KALA. Woodline Partners LP purchased a new stake in shares of KALA BIO in the first quarter worth about $1,483,000. Jane Street Group LLC purchased a new stake in KALA BIO in the fourth quarter valued at approximately $80,000. Virtu Financial LLC purchased a new stake in KALA BIO in the fourth quarter valued at approximately $48,000. XTX Topco Ltd purchased a new stake in KALA BIO in the second quarter valued at approximately $62,000. Finally, Geode Capital Management LLC raised its stake in KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after purchasing an additional 1,534 shares in the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对 KALA 的持股。Woodline Partners LP 在第一季度购买了 KALA BIO 的新股份，价值约为 1,483,000 美元。Jane Street Group LLC 在第四季度购买了 KALA BIO 的新股份，价值约为 80,000 美元。Virtu Financial LLC 在第四季度购买了 KALA BIO 的新股份，价值约为 48,000 美元。XTX Topco Ltd 在第二季度购买了 KALA BIO 的新股份，价值约为 62,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 KALA BIO 的股份增加了 2.8%。Geode Capital Management LLC 现在拥有该公司 56,367 股股票，价值 268,000 美元，此前在上个季度又购买了 1,534 股。24.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of KALA BIO in a report on Friday, March 27th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, KALA BIO has an average rating of &#34;Hold&#34; and a consensus price target of $20.38.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 3 月 27 日的报告中重申了对 KALA BIO 股票的 “卖出（e+）” 评级。一位分析师对该股票给予了买入评级，四位分析师给予了持有评级，一位分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，KALA BIO 的平均评级为 “持有”，共识目标价为 20.38 美元。</p>
</div><p><strong>View Our Latest Report on KALA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 KALA 的最新报告</strong></p>
</div><h2>KALA BIO Company Profile</h2>
<div class="lb-trans"><h2>KALA BIO 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>KALA Bio NASDAQ: KALA is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.</p>
<div class="lb-trans"><p>KALA Bio 纳斯达克：KALA 是一家商业阶段的生物制药公司，专注于开发和商业化用于眼部疾病的新疗法。该公司的专有表面电荷基础纳米颗粒递送平台旨在增强治疗药物在眼表面的渗透和滞留。这项技术是其主要产品 Eysuvis（KPI-121 1.0%）的基础，该产品是 FDA 批准的用于短期缓解与过敏性结膜炎相关的眼部瘙痒的局部类固醇。</p>
</div><p>Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.</p>
<div class="lb-trans"><p>除了其已批准的疗法外，KALA Bio 还在推进一系列针对炎症和退行性眼病的研究药物候选者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than KALA BIO</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 KALA BIO</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KALA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in KALA BIO Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 KALA BIO 吗？</h2>
</div><p>Before you consider KALA BIO, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 KALA BIO 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KALA BIO wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 KALA BIO 并不在名单上。</p>
</div><p>While KALA BIO currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 KALA BIO 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kala 制药（NASDAQ:KALA）公布季度财报结果